| pubmed-article:9829838 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C0007082 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C0018183 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C0178539 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C1521761 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C0205464 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:9829838 | lifeskim:mentions | umls-concept:C0442821 | lld:lifeskim |
| pubmed-article:9829838 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9829838 | pubmed:dateCreated | 1998-12-3 | lld:pubmed |
| pubmed-article:9829838 | pubmed:abstractText | Eighteen colorectal carcinoma patients without macroscopic disease after surgery were immunized using recombinant (r) human (h) carcinoembryonic antigen (CEA) with (n=9) or without (n=9) the addition of soluble granulocyte/macrophage-colony-stimulating factor (GM-CSF). The dose of rhCEA per immunization was 100 microg (n=6), 316 microg (n=6) or 1000 microg (n=6). rhCEA was given s.c. on day 1 and 80 microg/day of GM-CSF s.c. on days 1-4. The schedule was repeated six times during a period of 9 months. All patients in the GM-CSF group developed a strong rhCEA-dose-dependent IgG antibody response while only one-third of the non-GM-CSF patients mounted a weak antibody response. All patients (9/9) in the GM-CSF group developed a strong rhCEA-specific proliferative T cell response as well as type I T cells (interferon gamma secretion). In 45% of the patients also a weak type II T cell response (interleukin-4 secretion) was evoked. Both MHC-class-I- and -II restricted rhCEA-specific T cells were noted. A specific cellular response (proliferation and/or cytokine secretion) against native hCEA could be found in 8/9 patients in the GM-CSF group, although at a significantly lower level than against rhCEA. In the non-GM-CSF group a weak rhCEA-specific T cell response was induced. Three patients had a proliferative response, 4 patients type I T cells and 6 patients type II T cells. No signs of autoimmune reactions were noted. Local pharmacological administration of GM-CSF seemed to be a prerequisite for the induction of a strong immunity against baculovirus-produced hCEA protein. However, the cellular response against native CEA was of a significantly lower magnitude. | lld:pubmed |
| pubmed-article:9829838 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9829838 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829838 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9829838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829838 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9829838 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9829838 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:9829838 | pubmed:issn | 0340-7004 | lld:pubmed |
| pubmed-article:9829838 | pubmed:author | pubmed-author:SmithGG | lld:pubmed |
| pubmed-article:9829838 | pubmed:author | pubmed-author:WahrenBB | lld:pubmed |
| pubmed-article:9829838 | pubmed:author | pubmed-author:MellstedtHH | lld:pubmed |
| pubmed-article:9829838 | pubmed:author | pubmed-author:RudénUU | lld:pubmed |
| pubmed-article:9829838 | pubmed:author | pubmed-author:YeMM | lld:pubmed |
| pubmed-article:9829838 | pubmed:author | pubmed-author:StrigårdKK | lld:pubmed |
| pubmed-article:9829838 | pubmed:author | pubmed-author:FagerbergJJ | lld:pubmed |
| pubmed-article:9829838 | pubmed:author | pubmed-author:SamanciAA | lld:pubmed |
| pubmed-article:9829838 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9829838 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:9829838 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9829838 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9829838 | pubmed:pagination | 131-42 | lld:pubmed |
| pubmed-article:9829838 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:meshHeading | pubmed-meshheading:9829838-... | lld:pubmed |
| pubmed-article:9829838 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9829838 | pubmed:articleTitle | Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. | lld:pubmed |
| pubmed-article:9829838 | pubmed:affiliation | Department of Oncology, Karolinska Hospital, Stockholm, Sweden. | lld:pubmed |
| pubmed-article:9829838 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9829838 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9829838 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:9829838 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9829838 | lld:pubmed |
